Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Off-Label Use Potential With J&J’s Xarelto Not A Factor In Review, FDA Says

Executive Summary

In reviewing the approvability of Johnson & Johnson's factor Xa inhibitorXarelto (rivaroxaban), FDA must remain focused on the proposed indication - despite the inclination to factor in the risks associated with potential off-label use, Office of Oncology Drug Products Director Richard Pazdur said

You may also be interested in...



J&J Xarelto Liver Profile Key To Committee Vote; New Data Offer Assurance

The FDA advisory committee review of Johnson & Johnson's anticoagulant rivaroxaban highlights a recurring regulatory issue for the agency and its expert panels: how to assess newly available data that is not included in the NDA, but could be key to a product's approvability

Separating Gene Therapy ‘Wheat’ From ‘Chaff’: CBER Facilitators Could Help Inexperienced Sponsors

Surge of interest prompts US FDA to consider how to adjust feedback, including potentially creating a separate team to answer more basic questions.

FDA/Sponsor Meetings During COVID: How To Overcome The Loss Of ‘Hallway Chitchat’

When the closest you can get to US FDA staff is Webex, the meeting minutes and interactions with the review team project manager take on increased importance, consultants suggest during an Informa-sponsored webinar.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel